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Background/Aims: The proper assessment of the current 
disease status of patients with chronic hepatitis B would 
be valuable for establishing optimal management strate-
gies. Methods: The clinical and laboratory characteristics of 
2,954 patients with current or previous antiviral treatment 
(46.2±10.8 years, 69.7% male) enrolled from 46 referral 
hospitals and 129 local hospitals or clinics throughout Ko-
rea were analyzed. Results: The disease status included 
chronic hepatitis, cirrhosis, and hepatocellular carcinoma in 
79.9%, 16.4%, and 3.7% of the patients, respectively. The 
major mode of hepatitis B virus (HBV) infection was vertical 
transmission. The hepatitis C virus (HCV) co-infection rate 
was 1.5%; however, only 50.8% of patients were evaluated 
for HCV. The use of herbal or complementary medicines was 
reported in 33.5% of the patients. The majority of patients 
(97.6%) were treated with oral nucleoside/nucleotide ana-
logues. Several characteristics were different between the 
patients treated at referral hospitals and local hospitals/
clinics, including the disease state, choice of antiviral drug, 
and methods of HBV DNA measurement. Conclusions: This 
study provides a comprehensive picture of the clinical and 
laboratory characteristics of patients treated in Korea. Ef-
forts to optimize management strategies are warranted. (Gut 
Liver 2012;6:241-248)
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INTRODUCTION
Korea is an endemic area of hepatitis B virus (HBV) infec-
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tion.
1 The prevalence of HBV infection in Korea was 8% to 
15% before the introduction of hepatitis B vaccination in the 
early 1980s and its integration into universal vaccination for 
newborn infants in 1995.
2,3 The prevalence of hepatitis B sur-
face antigen (HBsAg) among Korean middle school students 
has markedly decreased from 3.2% in the late 1990s to 0.4% in 
2007 and HBsAg positivity in preschool children also decreased 
from 0.9% in 1995 to 0.2% in 2007.
3 However, the chronic HBV 
infection rate is still high, ranging from 2% to 8.9% in adults.
4-6 
Until now, HBV infection is a major etiology of liver cirrhosis 
and hepatocellular carcinoma (HCC) in Korea.
1 
Since the introduction of lamivudine to Korea in 1999, oral 
nucleoside or nucleotide analogues has been widely used for 
patients with chronic hepatitis B (CH-B). Significant changes 
in characteristics of CH-B patients have been suggested since 
the introduction of hepatitis B vaccination and antiviral agents 
in Korea. Proper assessment of characteristics of CH-B patients 
with antiviral treatment would be valuable for establishing the 
optimal management strategy for patients with HBV infection. 
However, most available data were based on non-representative 
or small sized samples from selected communities. In this study, 
we aimed to investigate clinical and laboratory features of HBV 
infected patients with current or past antiviral treatment across 
Korea to provide a more comprehensive picture of CH-B pa-
tients with antiviral therapy.
MATERIALS AND METHODS
1. Patients
From February 2009 to June 2009, a prospective survey was 242  Gut and Liver, Vol. 6, No. 2, April 2012
conducted for randomly selected patients aged 18 year or over 
and had current or past history of antiviral treatment for CH-B 
in outpatient clinic of 46 referral hospitals and 129 local clinics 
or hospitals across Korea. Numbers of the study candidates in 
each hospital were determined based on the geographic distribu-
tion of general population and prevalence of CH-B patients with 
antiviral treatment. Initially, randomly selected 3,218 patients 
agreed to participate in this study and replied to the question-
naires. Among them, 264 patients were excluded for the follow-
ing reasons: 1) those who were not followed up for at least 6 
months at the respective hospital or clinic (n=32), 2) those who 
did not received antiviral treatment (n=155), and 3) those who 
did not complete the survey (n=77). Finally, 2,954 patients were 
included and analyzed in this study. 
To get the representative samples, we allocated number of pa-
tients to be enrolled in each providence according to population 
statistics of the corresponding area. Patients were enrolled from 
Seoul (n=626), Incheon and Gyeonggi area (n=795), Gangwon 
area (n=86), Chungcheong area (Daejeon, Chungcheongnam-
do and Chungchengbuk-do; n=293), Gyeongsang area (Pusan, 
Daegu, Ulsan, Gyeongsangnam-do, and Gyeongsangbuk-do; 
n=813), and Jeolla area (Gwangju, Jeollanam-do, Jeollabuk-do, 
and and Jeju island; n=341) (Fig. 1). 
This study was conducted in accordance with the Declaration 
of Helsinki and Good Clinical Practice. The study protocol was 
approved by the Institutional Review Board of each respective 
hospital and informed consent was obtained before the survey.
2. Questionnaires
Questionnaires were comprised of two parts. First part, re-
corded by participating patients, included age, sex, use of herbal 
medicine and complementary medicine, and family history of 
HBV infection and HCC. Second part, filled by the participat-
ing doctors and investigators, consisted of age at diagnosis of 
chronic HBV infection, type of hospital, disease state, risk fac-
tors of infection, method of HBV DNA measurement, and labo-
ratory values. For the disease state, participating doctors were 
asked to provide current diagnosis of patients, and they selected 
most appropriate diagnosis from one of these 3 diagnoses 
(chronic hepatitis, cirrhosis, and HCC), according to the Korean 
Association for the Study of the Liver (KASL) guideline.
7,8 For 
the risk factors for HBV infection, family history of HBV-related 
liver disease, sexual contact, intravenous drug use, and transfu-
sion were assessed. For the laboratory values, alanine amino-
transferase (ALT), aspartate aminotransferase (AST), hepatitis 
B e antigen (HBeAg), and HBV DNA level were assessed at the 
nearest time point before starting antiviral treatment. HBeAg, 
ALT, AST, bilirubin, albumin, prothrombin time (PT) and plate-
let count was obtained at the nearest time of survey. Anti-HCV 
was also assessed, and analyzed.
3. Data analysis
The possible mode of infection was classified into 1) vertical 
transmission (from an infected mother to her baby), 2) horizon-
tal transmission (from one family member to another except 
mother-to-baby transmission), 3) other parenteral risk factors 
(history of sexual contact, IV drug use, or transfusion), and 4) 
unknown risk factors. Participating medical institutions were 
classified into referral hospitals and local clinics/hospitals. Clini-
cal and laboratory characteristics were evaluated according to 
type of hospitals and disease status. 
Statistical analysis was performed using the chi-square to 
compare discrete variables and the t-test or ANOVA for con-
tinuous variables using PASW Statistics 17.0 (SPSS Inc., Chi-
Fig. 1. The geographic distribution of the 
patients enrolled in the study (n=2,954). 
The patients with chronic hepatitis B were 
randomly selected from 46 referral hos-
pitals and 129 local clinics or hospitals 
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cago, IL, USA). A p-value of less than 0.05 was considered to be 
significant. 
RESULTS
1. Clinical and laboratory characteristics of the patients  
Age of 2,954 patients was 46.2±10.8 years (mean±SD) and 
male-to-female ratio was 2.3:1 (Table 1). HBV infection was 
diagnosed at age of 35.2±12.6 years (mean±SD). Family history 
of HBV infection was noticed in 1,829 (61.9%) patients. Siblings 
of the patients were reported to be most frequently affected by 
HBV infection (36.5%), followed by mothers (32.9%), children 
(10.4%), fathers (8.0%), and spouses (2.4%). Vertical transmis-
sion was major mode of infection (32.9%) followed by horizon-
tal transmission (23.7%) and other parenteral exposure (0.2%). 
However, no identifiable risk factors were noted in 43.2%. 
Family history of HCC was reported in 442 cases (15.0%). Nine 
hundred and ninety-one (33.5%) patients reported that they had 
taken herbal or complementary medicine. Disease status was 
chronic hepatitis (n=2,360, 79.9%), cirrhosis (n=484, 16.4%), 
and HCC (n=110, 3.7%).
When we further analyzed mode of infection according to 
age group, vertical transmission was more frequently found at 
young age. While vertical transmission was reported in 59.4% 
of patients younger than 30, it was noted in 47.0%, 32.1%, 
24.5%, and 13.3% of age groups 30 to 39, 40 to 49, 50 to 59, 
and 60 or older, respectively (p<0.001). In contrast, the por-
tion of patients with horizontal transmission was 13.2% in age 
group 18 to 29, it rose with increasing age until reaching its 
peak of 27.5% in age group 50 to 59 (Fig. 2). Many patients at 
older ages had unknown mode of transmission. 
HBeAg was positive in 80.4% of patients at the time of anti-
viral therapy (Table 2). HBeAg loss was seen in 26.8% of treated 
patients at the time of survey. Anti-HCV antibody was positive 
in 22 (1.5%) of 1,501 tested patients, but however, only 50.8% 
patients had evaluation for HCV. 
Fig. 2. The mode of infection according to age group. The possible 
mode of infection was different according to age groups. Vertical 
transmission was the major mode of infection in most age groups, 
including young patients.






Local hospital or clinic
(n=1,593)
p-value
Age, yr 46.2±10.8 47.4±10.6 45.0±10.8 <0.001
Male  2,060 (69.7) 942 (69.2) 1,158 (70.2) 0.56
Age at diagnosis, yr 35.2±12.6 35.4±12.6 36.0±12.5 0.41
Family history of hepatitis B virus infection  1,829 (61.9) 884 (65.0) 945 (59.3) 0.002
Mode of infection  0.077
  Vertical transmission 972 (32.9) 425 (31.2) 547 (34.3)
  Horizontal transmission 699 (23.7) 372 (27.3) 327 (20.5)
  History of sexual contact, IV drug use, or transfusion 7 (0.2) 2 (0.1) 5 (0.3)
  Unknown   1,276 (43.2) 562 (41.3) 714 (44.8)
Family history of hepatocellular carcinoma  442 (15.0) 254 (18.7) 188 (11.8) <0.001
Use of complementary medicine  991 (33.5) 464 (34.1) 527 (33.1) 0.56
  Herbal medicine  503 (17.0) 236 (17.3) 267 (16.7) 0.69
  Other alternative medicine 797 (26.9) 351 (25.7) 446 (27.9) 0.19
Disease state at survey  <0.001
  Chronic hepatitis 2,360 (79.9) 993 (73.0) 1,367 (85.8)
  Cirrhosis 484 (16.4) 277 (20.4) 207 (13.0)
  Hepatocelluar carcinoma 110 (3.7) 91 (6.7) 19 (1.2)
Data are presented as mean±SD or number (%).244  Gut and Liver, Vol. 6, No. 2, April 2012






Local hospital or clinic
(n=1,593)
p-value
Hepatitis e antigen positivity 
  At the start time of antiviral therapy* 2,264 (80.4) 947 (75.1) 1,307 (84.7) <0.001
  At the time of survey 1,705 (57.7) 728 (53.5) 977 (61.3) <0.001
Hepatitis e antigen loss
† 607 (26.8) 248 (35.9) 359 (27.5) 0.41
At the time of antiviral therapy
  AST, IU/L 95 (61-156) 94 (58-159) 96 (64-153) 0.12
  ALT, IU/L 118 (82-208) 115 (69-219) 120 (87-196) 0.33
  HBV DNA, log10 IU/mL 6.8 (5.6-7.3) 6.5 (5.3-7.3) 7.0 (5.8-7.3) <0.001
At the time of survey
  AST, IU/L 29 (23-42) 28 (22-40) 30 (23-44) 0.002
  ALT, IU/L 30 (20-47) 29 (19-44) 32 (21-52) 0.004
  Bilirubin, mg/dL 0.8 (0.6-1.1) 0.8 (0.6-1.1) 0.8 (0.6-1.0) <0.001
  Albumin, mg/dL 4.4 (4.1-4.6) 4.4 (4.1-4.6) 4.4 (4.1-4.6) 0.25
  PT, sec 12.5 (11.7-13.6) 12.7 (11.8-13.9) 12.2 (11.6-13.1) <0.001
  Platelet, ×10
3/mm
3 178 (135-224) 172 (123-221) 183 (145-229) <0.001
Anti HCV testing  1,501 (50.8) 775 (56.9) 726 (45.6) <0.001
  Anti HCV positive  22 (1.5) 12 (1.5) 10 (1.4) 0.78
Data are presented as the median (quartile) or number (%).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBV, hepatitis B virus; PT, prothrombin time; HCV, hepatitis C virus.
*A total of 2,817 patients (95.4%) had an available hepatitis B e antigen status at the time of antiviral therapy; 
†A total of 2,264 patients were 
hepatitis B e antigen-positive.










  Lamivudine 2,310 (78.2) 923 (67.8) 1,387 (87.1)
  Entecavir 0.5 mg 340 (11.5) 220 (16.2) 120 (7.5)
  Clevudine 185 (6.3) 137 (10.1) 48 (3.0)
  Adefovir 49 (1.7) 28 (2.1) 21 (1.3)
  Interferon/Peg-interferon 59 (2.0) 42 (3.1) 17 (1.1)
  Other 11 (0.4) 11 (0.8) 0
Treatment change at survey <0.001
  Discontinued therapy 184 (6.2) 126 (9.3) 58 (3.6)
  Using same drug 1,506 (51.1) 606 (44.8) 900 (56.5)
  Changed initial drug 1,256 (42.6) 521 (45.9) 635 (39.9)
Drug at the time of survey* <0.001
  Lamivudine 1,018 (36.9) 281 (22.9) 737 (48.0)
  Adefovir  489 (17.7) 180 (14.7) 309 (20.1)
  Adefovir+Lamivudine 481 (17.4) 245 (20.0) 236 (15.4)
  Entecavir 0.5 mg 445 (16.1) 292 (23.8) 153 (10.0)
  Entecavir 1.0 mg 116 (4.2) 84 (6.8) 32 (2.1)
  Clevudine 183 (6.6) 126 (10.3) 57 (3.7)
  Other 30 (1.1) 19 (1.5) 11 (0.7)
Data are presented as number (%).
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2. Treatment history of patients
Majority of patients (97.6%) have started therapy with oral 
nucleoside/nucleotide analogues (Table 3). Lamivudine com-
prised major proportion, however, initial drug of choice was 
rapidly changing according to prescribed year (Table 4). Use of 
entecavir and clevudine was increasing, while use of lamivudine 
was decreasing (p<0.001). At the time of survey, 51.1% are us-
ing the initial drug, 42.6% are using changed drug, and 6.2% 
discontinued therapy (Table 3). Many patients had changed the 
drug during therapy. Almost half of patients treated with lami-
vudine (50.5%) had changed their medication to other medica-
tions (Fig. 3). At the time of survey, use of adefovir significantly 
increased (35.1% as adefovir monotherapy or adefovir and 
lamivudine combination therapy) when compared to the start 
time of antiviral therapy (1.7%, p<0.001).
3. Characteristics according to disease status and HBeAg
While chronic hepatitis was more common at young age, ad-
vanced liver diseases were prevalent at old age. The proportion 
of patients with cirrhosis and HCC rose as their age increased 
(2.3%, 7.0%, 15.7%, 23.3%, and 27.8% for cirrhosis, and 0%, 
0.5%, 2.0%, 6.1%, and 11.5% for HCC in age group 18 to 29, 30 
to 39, 40 to 49, 50 to 59, and ≥60 years, respectively, p<0.001 
for all) (Fig. 4). When laboratory results were compared among 
the patients with different disease status, cirrhosis and HCC 
were associated with less frequent HBeAg positivity compared 
to hepatitis (Table 5). Patients with cirrhosis and HCC showed 
higher AST level, prolonged PT, high bilirubin level, lower albu-
min level, and low platelet count (Table 5). 
When compared according to HBeAg status, HBeAg (+) group 
was younger than HBeAg (-) group (45.1±10.6 vs 50.6±10.1 
years, mean±SD, p<0.001). HBV DNA levels of HBeAg (+) group 
was higher than those of HBeAg (-) group (6.7±1.4 vs 5.8±1.4 
log10 IU/mL, mean±SD, p<0.001). The portion of patients with 
advanced liver diseases was lower in HBeAg (+) group than 
those of HBeAg (-) group (15.8% vs 36.3%, p<0.001). 
4. Characteristics according to hospital type
Overall 1,361 patients (46.1%) were enrolled from referral 
hospitals and 1,593 patients (53.9%) were enrolled from local 
clinics/hospitals. Several characteristics differed according to 
hospital type. Patients from referral hospitals were older, had 
more patients with family history of HBV infection or HCC, and 
had more patients with cirrhosis or HCC compared to patients 
seen at local hospitals/clinics (Table 1). The HBeAg status at 
Fig. 3. Changes in the treatment at the time of survey. Almost half 
of the patients treated with lamivudine had changed medications at 
the time of survey. Black, gray, and white represent the patients who 
changed to another drug, used the initial drug prescribed, and discon-
tinued therapy at the time of survey, respectively.
Table 4. The Initial Drug Used for Antiviral Therapy according to the Year Prescribed and Hepatitis B e Antigen Status






  ≤2006 (n=1,664) 1,598 (96.0) 7 (0.4) 3 (0.2) 20 (1.2) 31 (1.9) 5 (0.3)
  2007 (n=549) 347 (63.2) 110 (20.0) 72 (13.1) 14 (2.6) 4 (0.7) 2 (0.4)
  ≥2008 (n=713) 342 (48.0) 222 (31.1) 110 (15.4) 15 (2.1) 24 (3.4)  0
Data are presented as number (%).
*Data were not available for 28 patients (0.9%); 
†p-value <0.001.
Fig. 4. The disease status according to age group. Although chronic 
hepatitis was dominant in young patients, cirrhosis and hepatocellu-
lar carcinoma were more prevalent in older patients.246  Gut and Liver, Vol. 6, No. 2, April 2012
the start of therapy, HBeAg status at the time of survey, serum 
levels of HBV DNA was also significantly different, as well as 
for several laboratory variables (Table 2). Lamivudine was more 
frequently used in local hospitals/clinics (Table 3). Regarding 
methods for measuring HBV DNA level, real-time PCR was used 
in 41 (89.1%) of 46 referral hospitals, but only in 38 (29.5%) of 
129 local clinics/hospitals (p<0.001, Table 6). 
DISCUSSION
The optimal management strategy of HBV infection might 
be different according to nation or respective regions. In this 
perspective, it is crucial to know current state of CH-B patients 
with antiviral treatment in the respective region. This study is 
the first, nation-wide survey that provides the clinical and labo-
ratory characteristics of patients with current or past antiviral 
treatment for hepatitis B in Korea. 
HBV is transmitted parenterally by contaminated blood 
or other body fluids through blood vessels, skin or mucous 
membrane.
9 The major mode of HBV infection is different by 
countries. In areas of low endemicity, most HBV infections are 
acquired through intravenous drug use or unprotected sexual 
activities, while in areas of high endemicity, perinatal trans-
mission is major mode.
10 Perinatal transmission was the most 
important route in Korea,
9 but after universal HBV vaccination 
program in Korea, shift in primary mode of HBV infection is 
expected. Nevertheless, this data shows that the major mode of 
HBV infection in CH-B with antiviral treatment is still vertical 
transmission (32.9%). HBV vaccination was integrated into uni-
versal vaccination program since 1995 in Korea.
3 Hence, we can 
hardly expect a significant preventive effect of vaccine against 
vertical transmission in the studied patients. Notably, no known 
risk factor for HBV infection was reported in a significant por-
tion of patients (43.2%). Ignorance or underreporting of risk 
factors by the patients is suggested. More efforts are warranted 
to get information on possible mode of infection from these 
patients, including maternal infection, sexual contact, or intra-
venous drug use.
HCV co-infection rate among our patients was 1.5%. The 
HCV co-infection rates in Korean CH-B vary with study popu-
lation. While co-infection rate of 23% was reported among 
intravenous drug users,
11 0.15% was noted by health promo-
tion center controls.
12 Possibility of HCV coinfection should be 
considered when we monitor the clinical course or consider an-
tiviral treatment in CH-B patients.
7,13 However, the test result of 
anti-HCV was available for only 50.8% of enrolled patients. Our 
data indicated that we should pay more attention to HCV co-
infection in our clinical practice for CH-B patients.















Age, yr 44.7±10.6 51.5±9.5 56.1±8.6 <0.001 <0.001 <0.001
% Male 69.1 70.7 79.1 0.50 0.026 0.075
% HBeAg (+)  61.1 45.0 41.8 <0.001 <0.001 0.54
AST, IU/L 28 (22-39) 36 (27-48) 39 (33-52) <0.001 <0.001 0.018
ALT, IU/L 29 (20-47) 34 (23-48) 34 (23-46) 0.001 0.061 0.90
PT, sec 12.3 (11.5-13.2) 13.2 (12.2-14.5) 13.8 (12.2-14.8) <0.001 <0.001 0.19
Bilirubin, mg/dL 0.8 (0.6-1.0) 0.9 (0.7-1.3) 0.9 (0.7-1.5) <0.001 <0.001 0.24
Albumin, mg/dL 4.4 (4.2-4.6) 4.2 (3.8-4.5) 4.1 (3.7-4.3) <0.001 <0.001 0.040
Platelet, ×10
3/mm
3 191 (154-234) 116 (82-154) 118 (75-158) <0.001 <0.001 0.83
The values [mean±SD or median (quartile)] were obtained at the nearest time point prior to the survey.
HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase, PT, prothrombin time.
Table 6. The Methods of HBV DNA Measurement Used in Referral Hospitals and Local Clinics/Hospitals 
Detection limit, IU/mL
Referral hospitals, No. (%)
(n=46)
Local clinics/hospitals, No. (%)
(n=129)
Hybrid capture assay 20,000 0 (0.0) 30 (23.3)
Branched-DNA assay 2,000 5 (10.9) 61 (47.2)
Real-time PCR assay 60 41 (89.1) 38 (29.5)
p<0.001.
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We also noticed that significant proportion of patients (33.5%) 
had taken or were taking herbal or complementary medicines. 
Arbitrary use of unauthorized drug can lead to side effect in-
cluding liver toxicity, drug interaction, or high cost in CH-B 
with antiviral treatment. It is momentous that physicians should 
be aware of use of these medicines by their patients.
14
Patterns of antiviral therapy also differ by region. For ex-
ample, adefovir-lamivudine combination therapy is used in 30% 
of nucleoside-naïve patients in France.
15 The use of antiviral 
agents in this study was collected from all-across Korea, which 
may give comprehensive picture of current status of antiviral 
therapy in Korea. Nevertheless, the data about antiviral therapy 
needs careful interpretation. This study did not intend to evalu-
ate efficacy or outcome of antiviral therapy, and patients started 
therapy at various time points, for example, patients who 
started antiviral therapy in earlier times had only one licensed 
drug (lamivudine). Nevertheless, several points can be drawn 
from this data. First, most patients in Korea are treated with nu-
cleoside/nucleotide analogues. Second, patients who are using 
adefovir dramatically increased at the time of survey compared 
to the start time of antiviral therapy, indicating that lamivudine 
experience and/or resistant patients may pose a significant pro-
portion of patients in near future. Third, significant proportion 
of patients was receiving adefovir monotherapy at the time of 
survey. As most patients had started therapy with lamivudine, 
majority of them is expected to be lamivudine-resistant patients, 
who are receiving sequential monotherapy. There are reports 
of multi-drug resistant mutants in patients who have received 
sequential monotherapy.
16 Hence, multi-drug resistant mutants 
may emerge as a clinical problem in future. Careful monitoring 
as well as effort to prevent development of antiviral-resistant 
HBV may be needed. 
We could also notice clinical and laboratory characteristics 
are different according to disease status and HBeAg status. 
These are in line with data from previous studies since HBeAg 
(-) CH-B patients represent a late stage in the course of chronic 
HBV infection.
17,18 We could also notice that clinical and labo-
ratory characteristics are different between patients treated at 
referral hospitals and patients treated at local hospitals/clinics. 
Patients treated at local hospitals/clinics were younger, had less 
advanced disease, and were treated with lamivudine. Further-
more, HBV DNA was measured by real-time PCR in minority 
of local clinics or hospitals (29.5%). Due to its high sensitiv-
ity, specificity, and accuracy and broad dynamic range, use of 
real-time PCR quantification assays is strongly recommended 
nowadays.
7,13,19 Especially, detection of low level viremia is 
essential for management of incomplete response or viral 
breakthrough.
7,13,20-22 Adoption of the more sensitive method 
is strongly warranted even in local clinics or hospitals. The 
observed differences between referral hospitals and local hos-
pitals/clinics warrant further studies. Most studies in Korea are 
performed in referral hospitals, and in order to comprehensively 
understand current status of HBV infection in Korea, more data 
from local hospitals/clinics is needed.
Our study has a few limitations as a cross-sectional study 
based on questionnaires, which, in turn, partly depended on 
retrospective data or memory of the patients and physician. For 
example, many patients, especially old ones, did not know HBV 
infection status of their parents. Hence, we might suggest that 
a significant portion of those with unknown risk factors had 
been vertically transmitted. Few data sets, such as HBeAg before 
antiviral therapy, were also incomplete. Since we included only 
patients with past or current antiviral therapy, population in 
this study does not represent all the patients with chronic HBV 
infection. Hence, patient’s characteristic would be different if 
those without antiviral treatement were included. For example, 
if we included patients in immune-tolerance phase, more pa-
tients may have been classified to have been infected by verti-
cal transmission and to be HBeAg positive. Despite a few weak 
points which were partly inevitable in this kind of study, we 
could present lots of valuable information on the current epide-
miology and laboratory findings in CH-B patients with antiviral 
therapy.
In conclusion, this study could provide comprehensive un-
derstanding about the clinical and laboratory characteristics of 
patients with antiviral therapy in Korea. Especially, we indicated 
several problems in current clinical practice for CH-B in Korea, 
in which imminent improvement is warranted. More efforts to 
optimize management strategy for patients with HBV infection 
in Korea are needed based on this data. 
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